Dimitra Dalampira

Thessaloniki, ESYE12, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics.

Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics.

Journal: American journal of hematology

Published: March 23, 2026

Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group on 175 Patients.

Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group on 175 Patients.

Journal: American journal of hematology

Published: March 06, 2025

Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?

Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?

Journal: Frontiers in oncology

Published: March 02, 2025

Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group.

Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 19, 2024

Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group.

Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 18, 2024

Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience.

Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience.

Journal: Journal of hematology

Published: September 02, 2024

Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.

Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.

Journal: International journal of cancer

Published: August 18, 2024

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG).

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG).

Journal: Leukemia & lymphoma

Published: August 14, 2024

Clinical characteristics and outcome of early-stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group.

Clinical characteristics and outcome of early-stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group.

Journal: Hematological oncology

Published: May 13, 2024

VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG).

VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG).

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 20, 2024

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group.

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group.

Journal: American journal of hematology

Published: April 14, 2024

Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.

Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.

Journal: American journal of hematology

Published: December 18, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026